NCT06563804 2026-03-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated
Clinical Trials
5 trialsNCT03922100 2026-03-18
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Nerviano Medical Sciences
Phase 1/2 Terminated
NCT03404193 2026-03-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04160052 2026-02-12
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated